{'fraction_non_alphanumeric': 0.0206794682422452, 'fraction_numerical': 0.0, 'mean_word_length': 4.895652173913043, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Chemoprevention of prostate cancer.

Are we making progress in the chemoprevention of prostate cancer? The disease is an ideal target: not only is it the most common cancer among men in the United States, it has the highest age-specific incidence of any cancer. If we could prevent the disease or delay its progression, many men could be spared the burden of diagnostic procedures and treatments, and costs to the health care system could be reduced substantially. Because we lack a complete understanding of the pathophysiology of prostate cancer, chemopreventive strategies have empirically focused on two approaches: treatment with antioxidants to reduce damage to DNA . . .